Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on February 22, 2011, reporting the issuance of $3 billion in senior notes to fund the acquisition of Dionex Corporation. The notes consist of $300 million in 2.050% Senior Notes due 2014, $900 million in 3.200% Senior Notes due 2016, and $1 billion in 4.500% Senior Notes due 2021. The net proceeds of approximately $2.18 billion are primarily earmarked for the Dionex acquisition, with any remaining funds to be used for general corporate purposes. The filing also details covenants, redemption provisions, and change-of-control clauses related to these notes. This strategic move signals Thermo Fisher's intent to expand its operations through significant inorganic growth.
Key Highlights
- 1Thermo Fisher Scientific issued $3 billion in senior notes across three tranches: $300M (2.050% due 2014), $900M (3.200% due 2016), and $1B (4.500% due 2021).
- 2The primary use of the net proceeds (~$2.18 billion) is to finance the acquisition of Dionex Corporation, with an estimated total purchase price of $2.1 billion.
- 3The issuance was conducted through a public offering under a Form S-3 registration statement.
- 4The notes are unsecured obligations, effectively subordinated to secured debt and structurally subordinated to subsidiary liabilities.
- 5The indenture includes provisions for mandatory redemption under specific circumstances, such as the failure to consummate the Dionex tender offer or termination of the merger agreement.
- 6The company retains the option to redeem the notes early, subject to certain conditions and premiums.
- 7Covenants in the indenture restrict the company's ability to incur secured debt, engage in sale-leaseback transactions, and sell all or substantially all of its assets.
Frequently Asked Questions
The primary purpose of the $3 billion senior notes issuance is to finance Thermo Fisher Scientific's acquisition of Dionex Corporation. The estimated purchase price for Dionex is $2.1 billion.
The notes are issued in three tranches: $300 million of 2.050% Senior Notes due 2014, $900 million of 3.200% Senior Notes due 2016, and $1 billion of 4.500% Senior Notes due 2021.
If the tender offer for Dionex shares is not completed by September 30, 2011, or if the merger agreement is terminated, Thermo Fisher will be required to redeem all of the issued notes at 101% of their principal amount, plus accrued interest.
The notes are general unsecured obligations and are effectively subordinated to any secured debt of Thermo Fisher. They are also structurally subordinated to all existing and future liabilities of its subsidiaries. However, they rank equally with other unsecured and unsubordinated indebtedness of the company.